5‐α‐Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review

•  To estimate the benefits and harms of 5‐α‐reductase inhibitors (5‐α‐RIs) in preventing prostate cancer.

[1]  C. Roehrborn,et al.  Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial. , 2011, European urology.

[2]  C. Roehrborn,et al.  Corrigendum to "The Effects of Combination Therapy with Dutasteride and Tamsulosin on Clinical Outcomes in Men with Symptomatic Benign Prostatic Hyperplasia: 4-Year Results from the CombAT Study" [Eur Urol 2010;57:123-31]. , 2010, European urology.

[3]  D. Tindall,et al.  Effect of dutasteride on the risk of prostate cancer. , 2010, The New England journal of medicine.

[4]  P. Lange.  Re: Effect of Dutasteride on the Risk of Prostate Cancer Andriole GL, Bostwick DG, Brawley OW, et al. REDUCE Study Group , 2010 .

[5]  C. Roehrborn,et al.  The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. , 2010, European urology.

[6]  T. Wilt,et al.  Five-alpha-reductase Inhibitors for prostate cancer prevention. , 2008, The Cochrane database of systematic reviews.

[7]  M. Kattan,et al.  Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. , 2007, Journal of the National Cancer Institute.

[8]  A. D'Amico,et al.  Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial. , 2007, The Lancet. Oncology.

[9]  A. D'Amico,et al.  Prostate cancer prevention and finasteride. , 2006, The Journal of urology.

[10]  I. Thompson,et al.  Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. , 2006, Journal of the National Cancer Institute.

[11]  S. Kaplan.  Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. , 2005, The Journal of urology.

[12]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[13]  Michael M Lieber,et al.  The influence of finasteride on the development of prostate cancer. , 2003, The New England journal of medicine.

[14]  P. Boyle,et al.  Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. , 2002, Urology.

[15]  Beverley Rader Lugo,et al.  Clinical Experience , 2009 .

[16]  E. Crawford,et al.  Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. , 1998, Urology.

[17]  M. Pike,et al.  The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen levels. , 1998, British Journal of Cancer.

[18]  M. Elhilali,et al.  Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study. , 1996, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[19]  F. Hamdy,et al.  Screening for Prostate Cancer , 2006 .

[20]  E. Round,et al.  CLINICAL-EXPERIENCE OF THE DETECTION OF PROSTATE-CANCER IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA TREATED WITH FINASTERIDE , 1994 .

[21]  E. Round,et al.  Clinical experience of the detection of prostate cancer in patients with benign prostate hyperplasia treated with finasteride. The Finasteride Study Group. , 1994, The Journal of urology.

[22]  P. Cangh,et al.  Finasteride (MK‐906) in the treatment of benign prostatic hyperplasia , 1993, The Prostate.

[23]  R C Bruskewitz,et al.  The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. , 2002, The New England journal of medicine.